CARL Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.…
Industry Peers
Health Information ServicesKey Statistics
About Carlsmed (NASDAQ: CARL)
›
Carlsmed (NASDAQ: CARL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 127 employees.
The shares were at 17.22 USD on 19 November 2026, up 40.6% over 52 weeks. Its 52-week range is 8.500 USD to 19.15 USD: the price is 10.1% below the high and 102.6% above the low.
Its market capitalisation is 471.90M USD.
Carlsmed reports return on equity of -30.0%, an operating margin of -59.0% and revenue up 64.9% year over year.
It holds more cash than debt, a net cash position of 58.42M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 22.00 USD is 27.8% above the current price. The next earnings report is expected on 25 February 2027.